Video Experimental Relacionado
Updated: Sep 9, 2025
04:59
Precision Ultrasound-guided Stem Cell Delivery for Vascular Repair in Aortic Diseases
Published on: June 20, 2025
300
Oportunidades terapéuticas del síndrome de Marfan: Perspectivas actuales
Xiaoying Feng1, Chao Qu2, Ping Jia3
1College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.
Drug design, development and therapy
|September 3, 2025
Resumen
El síndrome de Marfan (MFS), un trastorno genético que afecta al tejido conectivo, se entiende cada vez más a través de las nuevas tecnologías. La investigación está avanzando estrategias terapéuticas, incluida la terapia génica, para combatir sus graves complicaciones cardiovasculares.
Área de la Ciencia:
- La genética
- Biología molecular
- Medicina cardiovascular
Sus antecedentes:
- El síndrome de Marfan (MFS) es un trastorno hereditario del tejido conectivo causado por mutaciones en el gen de la fibrilina-1 (FBN1).
- Afecta a múltiples sistemas de órganos, especialmente los ojos, los huesos y el sistema cardiovascular, siendo este último el que presenta el mayor riesgo de mortalidad.
- Los tratamientos actuales se centran en el manejo de los síntomas y la prevención de eventos cardiovasculares potencialmente mortales.
Objetivo del estudio:
- Para revisar los avances recientes en las terapias del síndrome de Marfan.
- Destacar las metas terapéuticas emergentes y los tratamientos innovadores.
- Para discutir el potencial de la terapia génica para MFS.
Principales métodos:
- Revisión de la literatura actual sobre el tratamiento del síndrome de Marfan.
- Análisis de tecnologías emergentes como CRISPR-Cas9 y las células madre pluripotentes inducidas (iPSC).
- Exploración de nuevas plataformas de descubrimiento de fármacos y enfoques terapéuticos personalizados.
Principales resultados:
- Las nuevas tecnologías están profundizando en la comprensión de la diversidad de mutaciones de FBN1 y los mecanismos de la enfermedad.
- CRISPR-Cas9 e iPSCs ofrecen vías prometedoras para el descubrimiento de fármacos y la medicina personalizada.
- Las innovaciones quirúrgicas y los nuevos objetivos farmacológicos están mejorando el manejo de la EMF.
Conclusiones:
- Los recientes avances terapéuticos en el síndrome de Marfan incluyen avances quirúrgicos y farmacológicos.
- Las tecnologías emergentes están allanando el camino para tratamientos personalizados y una mejor comprensión de la enfermedad.
- La terapia génica tiene un potencial futuro significativo para el tratamiento del síndrome de Marfan.
Palabras clave:
Terapia genéticaPPC y sus derivadosSíndrome de Marfantratamiento farmacológicocirugíaMás Videos Relacionados
Videos de Conceptos Relacionados
01:24Cystic Fibrosis: Management
222
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
222
01:26Mitral Stenosis III: Medical Management
21
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
21
01:21Rheumatic Heart Disease III: Medical Management
31
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
31
01:26Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
01:30Aneurysm I: Introduction
25
An aortic aneurysm is a localized outpouching or dilation at a weak point in the artery wall. It may involve different parts of the aorta, such as the abdominal aorta, aortic arch, or thoracic aorta.Etiological factorsSeveral disorders are associated with aortic aneurysms.Congenital causes, such as primary connective tissue disorders like Marfan syndrome, impact the integrity and strength of connective tissues, notably affecting the aorta. Marfan syndrome is a genetic disorder that specifically...
25
01:29Cardiomyopathy V: Interprofessional Care
32
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
32